Berberine in the treatment of type 2 diabetes - literature review
DOI:
https://doi.org/10.12775/JEHS.2024.67.49000Keywords
berberine, type 2 diabetes, hyperglycemia, hyperlipidemiaAbstract
Introduction and purpose :
Type 2 diabetes is currently a serious problem worldwide. Each year, the number of individuals with carbohydrate metabolism disorders is increasing. This is due to an unhealthy lifestyle, lack of physical activity, and a diet rich in highly processed foods. Currently, the treatment of type 2 diabetes is based on the use of oral antidiabetic medications, with the first choice often being a derivative of biguanides, such as metformin. Berberine has been used in China for many years as a hypoglycemic agent, and its efficacy is compared to metformin preparations. This paper focuses on the benefits of using berberine in patients with prediabetes or type 2 diabetes and compares the effects of berberine preparations to classical medications used in diabetes treatment.
Material and methods :
The literaue was reviewed in PubMed and Google Scholar scientific database in 2013-2023 using the following keywords : berberine, diabetes mellitus type 2, hyperlipidemia, hyperglicemia
Conclusions :
The studies included in this manuscript have shown that berberine is a promising agent for adjunctive treatment in type 2 diabetes. It exhibits a range of positive effects such as lowering blood glucose levels, improving lipid profile, with no serious adverse effects reported. However, further research is needed to confirm these findings and develop an effective treatment plan.
References
Ahmad E, Lim S, Lamptey R, Webb DR, Davies MJ. Type 2 diabetes. The Lancet. 2022 Nov 19;400(10365):1803–20.
2. Antar SA, Ashour NA, Sharaky M, Khattab M, Ashour NA, Zaid RT, et al. Diabetes mellitus: Classification, mediators, and complications; A gate to identify potential targets for the development of new effective treatments. Biomedicine & Pharmacotherapy. 2023 Dec 1;168:115734.
3. Baska A, Leis K, Gałązka P. Berberine in the Treatment of Diabetes Mellitus: A Review. Endocr Metab Immune Disord Drug Targets [Internet]. 2021 Oct 23 [cited 2023 Dec 20];21(8):1379–86. Available from: https://pubmed.ncbi.nlm.nih.gov/33092516/
4. Och A, Podgórski R, Nowak R. toxins Biological Activity of Berberine-A Summary Update. [cited 2023 Dec 16]; Available from: https://pubmed.ncbi.nlm.nih.gov.
5. Rena G, Hardie DG, Pearson ER. The mechanisms of action of metformin. Diabetologia [Internet]. 2017 Sep 1 [cited 2024 Jan 6];60(9):1577. Available from: /pmc/articles/PMC5552828/
6. Kleibert M, Zygmunciak P, Łakomska K, Mila K, Zgliczyński W, Mrozikiewicz-Rakowska B. Insight into the Molecular Mechanism of Diabetic Kidney Disease and the Role of Metformin in Its Pathogenesis. Int J Mol Sci [Internet]. 2023 Sep 1 [cited 2024 Jan 6];24(17). Available from: /pmc/articles/PMC10487922/
7. Liu CS, Zheng YR, Zhang YF, Long XY. Research progress on berberine with a special focus on its oral bioavailability. Fitoterapia. 2016 Mar 1;109:274–82.
8. Feng X, Sureda A, Jafari S, Memariani Z, Tewari D, Annunziata G, et al. Berberine in Cardiovascular and Metabolic Diseases: From Mechanisms to Therapeutics. Theranostics [Internet]. 2019 [cited 2024 Feb 13];9(7):1923. Available from: /pmc/articles/PMC6485276/
9. Wang K, Feng X, Chai L, Cao S, Qiu F. The metabolism of berberine and its contribution to the pharmacological effects. Drug Metab Rev [Internet]. 2017 Apr 3 [cited 2024 Jan 5];49(2):139–57. Available from: https://pubmed.ncbi.nlm.nih.gov/28290706/
10. Xu X, Yi H, Wu J, Kuang T, Zhang J, Li Q, et al. Therapeutic effect of berberine on metabolic diseases: Both pharmacological data and clinical evidence. Biomedicine & Pharmacotherapy. 2021 Jan 1;133:110984.
11. Cheng M, Liu R, Wu Y, Gu P, Zheng L, Liu Y, et al. LC–MS/MS determination and urinary excretion study of seven alkaloids in healthy Chinese volunteers after oral administration of Shuanghua Baihe tablets. J Pharm Biomed Anal. 2016 Jan 25;118:89–95.
12. Zhang L, Wu X, Yang R, Chen F, Liao Y, Zhu Z, et al. Effects of Berberine on the Gastrointestinal Microbiota. Front Cell Infect Microbiol [Internet]. 2020 Feb 19 [cited 2024 Feb 13];10. Available from: /pmc/articles/PMC7933196/
13. Liu CS, Zheng YR, Zhang YF, Long XY. Research progress on berberine with a special focus on its oral bioavailability. Fitoterapia. 2016 Mar 1;109:274–82.
14. Yu Y, Liu L, Wang X, Liu X, Liu X, Xie L, et al. Modulation of glucagon-like peptide-1 release by berberine: In vivo and in vitro studies. Biochem Pharmacol. 2010 Apr 1;79(7):1000–6.
15. Pirillo A, Catapano AL. Berberine, a plant alkaloid with lipid-and glucose-lowering properties: From in vitro evidence to clinical studies. 2015 [cited 2023 Dec 27]; Available from: http://dx.doi.org/10.1016/j.atherosclerosis.2015.09.032
16. Och A, Podgórski R, Nowak R. Biological Activity of Berberine—A Summary Update. Toxins (Basel) [Internet]. 2020 Nov 1 [cited 2024 Jan 6];12(11). Available from: /pmc/articles/PMC7697704/
17. Liang Y, Xu X, Yin M, Zhang Y, Huang L, Chen R, et al. Effects of berberine on blood glucose in patients with type 2 diabetes mellitus: A systematic literature review and a meta-analysis. Endocr J. 2019;66(1).
18. Pirillo A, Catapano AL. Berberine, a plant alkaloid with lipid-and glucose-lowering properties: From in vitro evidence to clinical studies. 2015 [cited 2023 Dec 27]; Available from: http://dx.doi.org/10.1016/j.atherosclerosis.2015.09.032
19. Gong L, Wang R, Wang X, Liu J, Han Z, Li Q, et al. Research progress of natural active compounds on improving podocyte function to reduce proteinuria in diabetic kidney disease. Ren Fail. 2023 Dec 22;45(2).
20. Qin X, Jiang M, Zhao Y, Gong J, Su H, Yuan F, et al. Berberine protects against diabetic kidney disease via promoting PGC‐1α‐regulated mitochondrial energy homeostasis. Br J Pharmacol [Internet]. 2020 Aug 1 [cited 2024 Jan 9];177(16):3646. Available from: /pmc/articles/PMC7393204/
21. Sartore G, Ragazzi E, Antonello G, Cosma C, Lapolla A. Effect of a New Formulation of Nutraceuticals as an Add-On to Metformin Monotherapy for Patients with Type 2 Diabetes and Suboptimal Glycemic Control: A Randomized Controlled Trial. Nutrients [Internet]. 2021 Jul 1 [cited 2024 Jan 6];13(7). Available from: /pmc/articles/PMC8308828/
22. Rondanelli M, Riva A, Petrangolini G, Allegrini P, Giacosa A, Fazia T, et al. Berberine Phospholipid Is an Effective Insulin Sensitizer and Improves Metabolic and Hormonal Disorders in Women with Polycystic Ovary Syndrome: A One-Group Pretest–Post-Test Explanatory Study. Nutrients [Internet]. 2021 Oct 1 [cited 2024 Jan 6];13(10). Available from: /pmc/articles/PMC8538182/
23. Panigrahi A. Open Access BMC Endocrine Disorders. [cited 2023 Dec 27]; Available from: http://creativecommons.org/licenses/by/4.0/.TheCreativeCommonsPublicDomainDedicationwaiver
24. Tong X, Xu J, Lian F, Yu X, Zhao Y, Xu L, et al. Structural Alteration of Gut Microbiota during the Amelioration of Human Type 2 Diabetes with Hyperlipidemia by Metformin and a Traditional Chinese Herbal Formula: a Multicenter, Randomized, Open Label Clinical Trial. mBio [Internet]. 2018 May 1 [cited 2024 Jan 16];9(3). Available from: /pmc/articles/PMC5964358/
25. Ilyas Z, Perna S, Al-thawadi S, Alalwan TA, Riva A, Petrangolini G, et al. The effect of Berberine on weight loss in order to prevent obesity: A systematic review. Biomedicine & Pharmacotherapy. 2020 Jul 1;127:110137.
26. Guo HH, Shen HR, Wang LL, Luo ZG, Zhang JL, Zhang HJ, et al. Berberine is a potential alternative for metformin with good regulatory effect on lipids in treating metabolic diseases. Biomedicine & Pharmacotherapy. 2023 Jul 1;163:114754.
27. Rondanelli M, Gasparri C, Petrangolini G, Allegrini P, Avenoso D, Fazia T, et al. Berberine phospholipid exerts a positive effect on the glycemic profile of overweight subjects with impaired fasting blood glucose (IFG): a randomized double-blind placebo-controlled clinical trial. Eur Rev Med Pharmacol Sci [Internet]. 2023 Jul 1 [cited 2024 Jan 6];27(14):6718–27. Available from: https://pubmed.ncbi.nlm.nih.gov/37522683/
28. Zhao MM, Lu J, Li S, Wang H, Cao X, Li Q, et al. Berberine is an insulin secretagogue targeting the KCNH6 potassium channel. Nat Commun [Internet]. 2021 Dec 1 [cited 2024 Jan 6];12(1). Available from: /pmc/articles/PMC8460738/
29. Tuttle KR, Agarwal R, Alpers CE, Bakris GL, Brosius FC, Kolkhof P, et al. Molecular mechanisms and therapeutic targets for diabetic kidney disease. Kidney Int. 2022 Aug 1;102(2):248–60.
30. Gong L, Wang R, Wang X, Liu J, Han Z, Li Q, et al. Research progress of natural active compounds on improving podocyte function to reduce proteinuria in diabetic kidney disease. Ren Fail [Internet]. 2023 Dec 22 [cited 2024 Jan 9];45(2):2290930. Available from: https://www.tandfonline.com/doi/abs/10.1080/0886022X.2023.2290930
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Aleksandra Mazurek, Mateusz Pawlicki, Karol Stachyrak, Dawid Mika, Bartosz Mazur, Kamila Turek, Maciej Lambach, Anna Greguła, Aleksandra Kłos, Wiktoria Wilanowska
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 566
Number of citations: 0
